200
Participants
Start Date
December 30, 2020
Primary Completion Date
March 1, 2026
Study Completion Date
March 1, 2026
PD-1 antibody
neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy
Gemcitabine
neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles
Cisplatin
neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
IMRT
70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
RECRUITING
Jiangxi Cancer Hospital, Nanchang
RECRUITING
Pingxiang Peoples' Hospital, Pingxiang
RECRUITING
Jiujiang University Affiliated Hospital, Jiujiang
RECRUITING
Ganzhou Cancer Hospital, Ganzhou
RECRUITING
First Affiliated hospital of Gannan Medical University, Guangzhou
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Suizhou Central Hospital, Suizhou
Jiangxi Provincial Cancer Hospital
OTHER